M1FG
SUPN icon

Mach-1 Financial Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Mach-1 Financial Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,685
Closed -$317K – 293
2025
Q1 		$317K Buy
+9,685
New +$343K 0.1% 181
2024
Q1 		– Sell
-14,554
Closed -$421K – 201
2023
Q4 		$421K Buy
+14,554
New +$386K 0.16% 156

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Mach-1 Financial Group's SUPN Position: Q2 2025 in Review

Mach-1 Financial Group sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 9,685 shares — an estimated $317K sold.

Mach-1 Financial Group first reported a position in SUPN in Q4 2023 and held it in 2 quarters. The position peaked at $421K in Q4 2023. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Mach-1 Financial Group reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 9,685 Supernus Pharmaceuticals shares in Q2 2025, an estimated $317K.
  • Mach-1 Financial Group first reported a position in Supernus Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Mach-1 Financial Group's Supernus Pharmaceuticals position peaked at $421K in Q4 2023.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Mach-1 Financial Group's 13F filing for Q2 2025, filed 11 Aug 2025.